Megakaryocyte-Associated tyrosine Kinase (MATK) (N-Term), (AA 1-30) antibody

Details for Product No. ABIN392103
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Synonyms CHK, CTK, HHYLTK, HYL, HYLTK, Lsk, Batk, Ntk, si:ch211-63j24.2
N-Term, AA 1-30
(3), (3), (2), (2), (2), (1), (1), (1), (1)
(40), (23), (19), (12), (12), (12), (1)
(32), (12)
Clonality (Clone)
Polyclonal ()
(1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Western Blotting (WB)
(35), (20), (10), (7), (7), (7), (1), (1)
Pubmed 4 references available
Catalog no. ABIN392103
Quantity 400 µL
291.50 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen This MATK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 AA from the N-terminal region of human MATK.
Clone RB03166
Isotype Ig
Specificity This MATK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1~30 amino acids from the N-terminal region of human MATK.
Purification This antibody is purified through a protein A column, followed by peptide affinity purification.
Alternative Name MATK
Background MATK has amino acid sequence similarity to Csk tyrosine kinase and has the structural features of the CSK subfamily: SRC homology SH2 and SH3 domains, a catalytic domain, a unique N terminus, lack of myristylation signals, lack of a negative regulatory phosphorylation site, and lack of an autophosphorylation site. This protein is thought to play a significant role in the signal transduction of hematopoietic cells. It is able to phosphorylate and inactivate Src family kinases, and may play an inhibitory role in the control of T-cell proliferation. This protein might be involved in signaling in some cases of breast cancer.
Synonyms: Megakaryocyte-associated tyrosine-protein kinase, Tyrosine-protein kinase CTK, Protein kinase HYL, Hematopoietic consensus tyrosine-lacking kinase
Molecular Weight 56469 DA
Gene ID 4145
UniProt P42679
Research Area Phospho-specific antibodies, Cell Signaling, Protein Modifications, Cancer, Cell Cycle, Cell Structure
Application Notes WB = 1:1000
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date 6 months
Supplier Images
anti-Megakaryocyte-Associated tyrosine Kinase (MATK) (N-Term), (AA 1-30) antibody MATK Antibody (M1) (ABIN392103) western blot analysis in HL-60 cell line lysates (35 µg/lane).This demonstrates the MATK antibody detected the MATK protein (arrow).
Background publications Avraham, Jiang, Ota et al.: "Structural and functional studies of the intracellular tyrosine kinase MATK gene and its translated product." in: The Journal of biological chemistry, Vol. 270, Issue 4, pp. 1833-42, 1995 (PubMed).

Jhun, Rivnay, Price et al.: "The MATK tyrosine kinase interacts in a specific and SH2-dependent manner with c-Kit." in: The Journal of biological chemistry, Vol. 270, Issue 16, pp. 9661-6, 1995 (PubMed).

Kim, Zagozdzon, Meisler et al.: "Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer." in: The Journal of biological chemistry, Vol. 277, Issue 39, pp. 36465-70, 2002 (PubMed).

Zagozdzon, Bougeret, Fu et al.: "Overexpression of the Csk homologous kinase facilitates phosphorylation of Akt/PKB in MCF-7 cells." in: International journal of oncology, Vol. 21, Issue 6, pp. 1347-52, 2002 (PubMed).

Hosts (32), (12)
Reactivities (40), (23), (19), (12), (12), (12), (1)
Applications (35), (20), (10), (7), (7), (7), (1), (1)
Conjugates (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Epitopes (3), (3), (2), (2), (2), (1), (1), (1), (1)
back to top